AHA: Half of U.S. Adults Are Eligible for Treatment With Semaglutide

Follow Drugslib on

Medically reviewed by Carmen Pope, BPharm. Last updated on Nov 22, 2024.

By Lori Solomon HealthDay Reporter

FRIDAY, Nov. 22, 2024 -- More than half of all U.S. adults are eligible for semaglutide therapy, according to a research letter published online Nov. 18 in JAMA Cardiology to coincide with the American Heart Association Scientific Sessions 2024, held from Nov. 16 to 18 in Chicago.

Ivy Shi, M.D., from the Beth Israel Deaconess Medical Center in Boston, and colleagues used data from 25,531 participants in the National Health and Nutrition Examination Survey (2015 to March 2020) to quantify the number of U.S. adults eligible for semaglutide. Eligibility criteria included: (1) diabetes; (2) weight management (body mass index [BMI] ≥30 kg/m2 or BMI ≥27 kg/m2 with a weight-related comorbidity [hypertension, hyperlipidemia, or history of myocardial infarction or stroke]); and (3) secondary prevention of cardiovascular disease (CVD; aged 45 years or older, BMI ≥27 kg/m2, and a history of myocardial infarction or stroke).

The researchers found that semaglutide was indicated for an estimated 35.0 million adults for diabetes management, 129.2 million adults for weight management, and 8.9 million adults for secondary prevention of CVD. Of the 39.3 million U.S. adults eligible for semaglutide for diabetes or secondary prevention of CVD, 13.0 million were insured by Medicare and 4.7 million were insured by Medicaid.

"Efforts to increase equitable uptake should be coupled with strategies to ensure that the cost of semaglutide is commensurate with the value of the health benefits it produces," the authors write.

Abstract/Full Text

More Information

Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.

Source: HealthDay

Posted : 2024-11-23 06:00

Read more

Disclaimer

Every effort has been made to ensure that the information provided by Drugslib.com is accurate, up-to-date, and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. Drugslib.com information has been compiled for use by healthcare practitioners and consumers in the United States and therefore Drugslib.com does not warrant that uses outside of the United States are appropriate, unless specifically indicated otherwise. Drugslib.com's drug information does not endorse drugs, diagnose patients or recommend therapy. Drugslib.com's drug information is an informational resource designed to assist licensed healthcare practitioners in caring for their patients and/or to serve consumers viewing this service as a supplement to, and not a substitute for, the expertise, skill, knowledge and judgment of healthcare practitioners.

The absence of a warning for a given drug or drug combination in no way should be construed to indicate that the drug or drug combination is safe, effective or appropriate for any given patient. Drugslib.com does not assume any responsibility for any aspect of healthcare administered with the aid of information Drugslib.com provides. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse or pharmacist.

Popular Keywords